Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sustained annual growth of more than 3.4% in sales of prostate cancer therapies from 2005 to 2015 will be driven primarily by new entries to the market that will add to, rather than replace, existing therapies in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.
PR Newswire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
FDA Issues Warning Over Unapproved Breast Implant Device
The FDA said that the surgeon has been advertising the unapproved device on his web site.
FDA Recognizes Polish, Slovenian Inspections
Regulators on both sides of the Atlantic are optimistic they’ll meet the deadline, which they hope will allow them to direct more inspection resources elsewhere.
FDAnews Drug Daily Bulletin
SUSTAINED 3.4% ANNUAL SALES GROWTH IN THE PROSTATE CANCER DRUG MARKET WILL BE DRIVEN BY DEVELOPMENT OF NEW THERAPIES
June 8, 2006
